Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A DANISH national cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources

    Research output: Contribution to journalReviewResearchpeer-review

  4. Temporal variation in out-of-hospital cardiac arrest occurrence in individuals with or without diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To investigate the association between recent statin exposure and risk of severe COVID-19 infection and all-cause mortality in patients with COVID-19 in Denmark.

DESIGN AND SETTING: Observational cohort study using data from Danish nationwide registries.

PARTICIPANTS: Patients diagnosed with COVID-19 from 22 February 2020 to 17 May 2020 were followed from date of diagnosis until outcome of interest, death or 17 May 2020.

INTERVENTIONS: Use of statins, defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis.

PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality, severe COVID-19 infection and the composite.

RESULTS: The study population comprised 4842 patients with COVID-19 (median age 54 years (25th-75th percentile, 40-72), 47.1% men), of whom 843 (17.4%) redeemed a prescription of statins. Patients with statin exposure were more often men and had a greater prevalence of comorbidities. The median follow-up was 44 days. After adjustment for age, sex, ethnicity, socioeconomic status and comorbidities, statin exposure was not associated with a significantly different risk of mortality (HR 0.96 (95% CI 0.78 to 1.18); 30-day standardised absolute risk (SAR), 9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%); SAR difference, -0.4% (-1.9% to 1.2%)), severe COVID-19 infection (HR 1.16 (95% CI 0.95 to 1.41); 30-day SAR, 13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%); SAR difference, 1.9% (-0.7% to 4.5%)), and the composite outcome of all-cause mortality or severe COVID-19 infection (HR 1.05 (95% CI 0.89 to 1.23); 30-day SAR, 17.6% (16.4% to 18.8%) vs 18.2% (16.4% to 20.1%); SAR difference, 0.6% (-1.6% to 2.9%)). The results were consistent across subgroups of age, sex and presumed indication for statin therapy. Among patients with statin exposure, there was no difference between statin drug or treatment intensity with respect to outcomes.

CONCLUSIONS: Recent statin exposure in patients with COVID-19 infection was not associated with an increased or decreased risk of all-cause mortality or severe infection.

Original languageEnglish
Article numbere044421
JournalBMJ Open
Issue number12
Pages (from-to)e044421
Publication statusPublished - 4 Dec 2020

    Research areas

  • cardiology, COVID-19, epidemiology

ID: 61404274